Literature DB >> 6317115

Modulation of the concentration of noradrenaline at the neuro-effector junction in human saphenous vein.

W Janssens, R Verhaeghe.   

Abstract

We studied the importance of neuronal and extraneuronal uptake and of the pre-junctional alpha-adrenergic feed-back mechanism for the junctional noradrenaline concentration in the human saphenous vein. All major metabolites of the enzymatic breakdown of noradrenaline were detected in the overflow of superfused veins loaded with [3H]-noradrenaline. The efflux of 3,4-dihydroxyphenylglycol (DOPEG) was drastically reduced in preparations labelled after neuronal uptake blockade indicating its neuronal origin; the other metabolites are formed extraneuronally since they behaved distinctly differently from DOPEG under several experimental conditions. Extraneuronal uptake followed by enzymatic breakdown removes the same amount of noradrenaline from the biophase during nerve activity as that diffusing intact out of the tissue, whereas neuronal uptake appears only half as effective since the overflow of intact noradrenaline increases by only 48% in the presence of desmethylimipramine (DMI). However, in preparations mounted for isometric tension recording, neuronal uptake blockade potentiated contractions to alpha-adrenergic activation, emphasizing the functional importance of the neuronal disposition mechanism. By contrast, no evidence was found for a hydrocortisone-sensitive extraneuronal uptake compartment, suggesting that extraneuronal removal may have little, if any, functional importance. During nerve stimulation, yohimbine increased the amount of labelled noradrenaline present in the superfusate, while exogenously added noradrenaline decreased it in the presence of cocaine. Thus, prejunctional alpha-adrenoceptors can modulate the junctional concentration of neurotransmitter in the human saphenous vein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6317115      PMCID: PMC2044876          DOI: 10.1111/j.1476-5381.1983.tb11032.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Supersensitivity to catecholamines after impairment of extraneuronal uptake or catechol-O-methyl transferase.

Authors:  U Trendelenburg; K H Graefe
Journal:  Fed Proc       Date:  1975-09

2.  Frequency-dependence of 3H-noradrenaline secretion from human vasoconstrictor nerves: modification by factors interfering with alpha-or beta-adrenoceptor or prostaglandin E2 mediated control.

Authors:  L Stjärne; J Brundin
Journal:  Acta Physiol Scand       Date:  1977-10

3.  Neuronal and extraneuronal outflow of 3H-noradrenaline induced by electrical-field stimulation of an isolated blood vessel.

Authors:  J Schrold; O A Nedergaard
Journal:  Acta Physiol Scand       Date:  1977-10

4.  Prostaglandin E2- and alpha- or beta-adrenoceptor mediated interferences with 3H-noradrenaline secretion from human vasomotor nerves: comparison between effects on omental arteries and veins.

Authors:  L Stjärne; J Brudin
Journal:  Acta Physiol Scand       Date:  1977-06

5.  Determination of 3H-norepinephrine and its metabolites in superfusate from isolated blood vessels.

Authors:  T J Verbeuren; E Coen; P M Vanhoutte
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-05

6.  Selective metabolic pathways for noradrena-line in the peripheral and in the central nervous system.

Authors:  S Z Langer
Journal:  Med Biol       Date:  1974-12

7.  The potentiation of responses to adrenergic nerve stimulation in the presence of cocaine: its relationship to the metabolic fate of released norepinephrine.

Authors:  S Z Langer; M A Enero
Journal:  J Pharmacol Exp Ther       Date:  1974-12       Impact factor: 4.030

8.  The effect of hydrocortisone on the sensitivity of the isolated nictitating membrane to catecholamines: Relationship to extraneuronal uptake and metabolism.

Authors:  K H Graefe; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

9.  Inhibition of norepinephrine- 3 H release from sympathetic nerve endings in veins by acetylcholine.

Authors:  P M Vanhoutte; R R Lorenz; G M Tyce
Journal:  J Pharmacol Exp Ther       Date:  1973-05       Impact factor: 4.030

10.  Affinity of Noradrenaline and dopamine for neural alpha-receptors mediating negative feedback control of noradrenaline secretion in human vasoconstrictor nerves.

Authors:  L Stjärne; J Brundin
Journal:  Acta Physiol Scand       Date:  1975-09
View more
  6 in total

1.  Pre- and post-junctional effects of adenosine triphosphate on noradrenergic transmission in the rabbit ear artery.

Authors:  H Miyahara; H Suzuki
Journal:  J Physiol       Date:  1987-08       Impact factor: 5.182

2.  Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5-HT 1D subtype.

Authors:  G J Molderings; K Werner; J Likungu; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

3.  Facilitatory presynaptic angiotensin receptors on the sympathetic nerves of the human saphenous vein and pulmonary artery. Potential involvement in beta-adrenoceptor-mediated facilitation of noradrenaline release.

Authors:  G J Molderings; J Likungu; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

4.  SK&F 104078, a post-junctionally selective alpha 2-adrenoceptor antagonist in the human saphenous vein in vitro.

Authors:  S P Roberts; J Kelly; M A Cawthorne; M V Sennitt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

5.  Transmitter release modulated by alpha-adrenoceptor antagonists in the rabbit mesenteric artery: a comparison between noradrenaline outflow and electrical activity.

Authors:  S Mishima; H Miyahara; H Suzuki
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

6.  A study of ATP as a sympathetic cotransmitter in human saphenous vein.

Authors:  L C Rump; I von Kügelgen
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.